GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C5513 S-2 MethanandamideSummary: potent CB1 receptor agonist -
C5416 REV 5901Summary: antagonist of cysteinyl-leukotriene receptors -
B5104 SB 200646 hydrochlorideSummary: 5-HT2C/2B receptor antagonist -
B5106 MRS 1334Summary: antagonist for the human adenosine A3 receptor -
B5109 Noladin etherSummary: Endogenous agonist for the GPR55 and CB1 receptors -
B5112 BMY 14802 hydrochlorideSummary: Sigma receptor antagonist -
B5113 BMS 182874 hydrochlorideSummary: ETA antagonist -
B5125 LY 288513Summary: Selective CCK2 receptor antagonist -
B5164 NECASummary: adenosine receptor agonist, non-selective -
B5263 ZD 2079Summary: β3-adrenoceptor agonist

